Leadership Overview
Canadian Blood Services has 4 executives leading key functions including strategy, information technology, finance, and operations.
Dedicated to advancing Canada's health, Canadian Blood Services operates as a vital non-profit organization, ensuring the availability of essential blood, plasma, and stem cell donations across the nation through a robust and efficient service model.
Dedicated to advancing Canada's health, Canadian Blood Services operates as a vital non-profit organization, ensuring the availability of essential blood, plasma, and stem cell donations across the nation through a robust and efficient service model.
Leadership Roles at Canadian Blood Services
Graham Sher - Chief Executive Officer
Graham Sher, the Chief Executive Officer at Canadian Blood Services, directs the organization's overarching strategy and operational framework. This leadership role involves guiding the non-profit's mission to provide essential blood, plasma, and stem cell donation services throughout Canada. Sher ensures alignment with national health objectives and fosters innovation in donation collection and distribution processes. The Chief Executive Officer oversees critical partnerships with healthcare providers and government bodies, maintaining the integrity and efficiency of the national supply chain for life-saving biological materials. By focusing on donor engagement and public trust, Graham Sher drives the organization's commitment to meeting Canada's ongoing needs for these vital resources, ensuring a stable and reliable system for all Canadians.
Jennifer Camelon - Corporate Services Chief Financial Officer & Vice President
Jennifer Camelon, the Corporate Services Chief Financial Officer & Vice President at Canadian Blood Services, manages the organization's financial health and corporate services operations. This senior leadership position encompasses overseeing all financial planning, budgeting, accounting, and reporting functions, ensuring fiscal responsibility and sustainability for the non-profit. Camelon directs the strategic allocation of resources to support the critical mission of providing blood, plasma, and stem cell donations across Canada. The Corporate Services Chief Financial Officer & Vice President also oversees essential corporate functions, including human resources and legal affairs, ensuring operational compliance and efficiency. By maintaining strong financial controls and driving strategic financial initiatives, Jennifer Camelon safeguards the organization's ability to deliver vital healthcare services and meet the ongoing needs of Canadians.
Riley Neudecker - Co-President
Riley Neudecker, the Co-President at Canadian Blood Services, shares responsibility for driving the organization's strategic direction and operational execution. This leadership role focuses on advancing the mission of providing essential blood, plasma, and stem cell donation services throughout Canada. Neudecker collaborates with other senior leaders to enhance donor engagement, optimize collection processes, and ensure the efficient distribution of life-saving biological products nationwide. The Co-President oversees key initiatives aimed at strengthening the national donation network and fostering public trust in Canadian Blood Services. By championing innovation and operational excellence, Riley Neudecker contributes significantly to the organization's capacity to meet the continuous demand for critical medical resources, ensuring the health and well-being of Canadians.
Ali Ghaemi - Chief Information Officer
Ali Ghaemi, the Chief Information Officer at Canadian Blood Services, architects the organization's technology infrastructure and digital transformation initiatives. This executive position involves overseeing all aspects of information systems, data management, and cybersecurity to support the critical functions of blood, plasma, and stem cell donation services. Ghaemi drives the implementation of advanced technological solutions that enhance operational efficiency, improve donor experience, and ensure the secure handling of sensitive patient and donor information across Canada. The Chief Information Officer plays a pivotal role in leveraging data analytics to optimize inventory management and distribution networks, directly impacting the availability of life-saving donations. Through strategic technology planning, Ali Ghaemi ensures Canadian Blood Services maintains a robust and secure digital environment, capable of adapting to evolving healthcare demands and technological advancements.
Explore Leadership Teams in Blood & Organ Banks
Novavax, Inc. is a biotechnology company incorporated in 1987 and headquartered in Gaithersburg, Maryland, focused on discovering, developing, and commercializing vaccines to protect against serious infectious diseases. The company's proprietary technology platform combines a recombinant protein approach, nanoparticle technology, and a patented adjuvant to enhance immune response. Novavax's pipeline spans vaccine candidates targeting infectious diseases including COVID-19, influenza, respiratory syncytial virus, malaria, shingles, and other pathogens, with ongoing exploration of its adjuvant platform in oncology. The company maintains a strategic partnership with Sanofi for COVID-19 vaccine commercialization and has established licensing and collaboration agreements with major global pharmaceutical companies. Novavax trades on the NASDAQ under the ticker symbol NVAX.
Company Leadership DB
RM
LF
BL
Serum Institute of India Pvt. Ltd., founded in 1966 and headquartered in Pune, India, is a manufacturer of immunobiological drugs including vaccines in India.
Company Leadership PD
MC
Founded in 1987 and headquartered in Edison, New Jersey, MTF Biologics is a tissue bank that offers allograft tissue transplant services, orthopedics, wound care, reconstructive surgery, and more.
Company Leadership FE
MK
DA
MS
Emergent BioSolutions Inc., a life sciences company, provides preparedness and response solutions for accidental, deliberate, and naturally occurring public health threats in the United States. The company offers NARCAN Nasal Spray for the emergency treatment of known or suspected opioid overdose; Vaxchora vaccine for the prevention of cholera; Vivotif vaccine for oral administration for the prevention of typhoid fever; Anthrasil for the treatment of inhalational anthrax; BioThrax, an anthrax vaccine; CYFENDUS for post-exposure prophylaxis of disease following suspected or confirmed exposure to Bacillus anthracis; and Raxibacumab injection for the treatment and prophylaxis of inhalational anthrax. It also provides ACAM2000, a smallpox vaccine; CNJ-016 to address complications from smallpox vaccination; TEMBEXA for the treatment of smallpox disease caused by variola virus in adult and pediatric patients; BAT for the treatment of symptomatic botulism; Ebanga for the treatment of Ebola; Reactive Skin Decontamination Lotion Kit to remove or neutralize chemical warfare agents from the skin; Trobigard, a atropine sulfate obidoxime chloride auto-injector. In addition, the company is developing CGRD-001 for the treatment of poisoning by organophosphorus nerve agents or organophosphorus compounds; EBS-LASV to prevent Lassa fever; EBS-MARV to prevent Marburg virus disease; EBS-SUDV to prevent Sudan virus disease; Pan-Ebola mAbs for the treatment of ebola virus; SIAN Antidote for initial treatment of certain or suspected acute cyanide poisoning; UniFlu for immunity against influenza A and B viruses; and WEVEE-VLP for equine encephalitis virus infections. Further, it provides contract development and manufacturing services comprising drug substance and product manufacturing, and packaging, as well as technology transfer, process, and analytical development services. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
Company Leadership MP
HA
KL
SL
Frequently Asked Questions Regarding Canadian Blood Services Top Executives and Leadership Team
